Ignite Creation Date:
2024-05-06 @ 7:43 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02587325
Status:
COMPLETED
Last Update Posted:
2023-01-31
First Post:
2015-10-23
Brief Title:
Phase 11b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
Sponsor:
Aadi Bioscience Inc
Organization:
Aadi Bioscience Inc
Study Overview
Official Title:
A Phase 11b Clinical Trial of ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension PAH
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None